Last reviewed · How we verify
Nicotine Prototype Mini lozenge
At a glance
| Generic name | Nicotine Prototype Mini lozenge |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Bioequivalence Study of Two Nicotine Lozenges in Fasting Conditions in Healthy Smokers (PHASE1)
- To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicotine Prototype Mini lozenge CI brief — competitive landscape report
- Nicotine Prototype Mini lozenge updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI